Evidence map›Paper›PMID 40747481›Full record

ArticleUrology case reports2025

Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report.

Shinkuro Yamamoto, Satoshi Fukata, Takashi Karashima, Atsushi Kurabayashi, Rie Yoshimura, Kaoru Furihata, Yuhei Shiba, Tomoya Nao, Hirofumi Satake, Keiji Inoue

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shinkuro YamamotoDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Satoshi FukataDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Takashi KarashimaDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Atsushi KurabayashiDepartment of Pathology, Kochi Medical School, Nankoku, 783-8505, Japan.
Rie YoshimuraDepartment of Urology, Kochi Prefectural Aki General Hospital, Aki, 784-0027, Japan.
Kaoru FurihataDepartment of Pathology, Kochi Medical School, Nankoku, 783-8505, Japan.
Yuhei ShibaDepartment of Pathology, Chikamori Hospital, Kochi, 780-8522, Japan.
Tomoya NaoDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Hirofumi SatakeDepartment of Pathology, Chikamori Hospital, Kochi, 780-8522, Japan.
Keiji InoueDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) with rhabdoid features is a rare and highly aggressive condition with no established treatment for early recurrence. We herein report a case involving a 58-year-old man who underwent nephrectomy for clear-cell RCC with rhabdoid features and developed rapid metastases within 3 months. Treatment with pembrolizumab plus lenvatinib achieved a sustained partial response, except for vertebral metastasis. Thereafter, radiotherapy was added, and systemic therapy resumed, which maintained disease control for 2 years. Immunohistochemistry revealed partial PD-L1 expression in rhabdoid areas. This case highlights the potential efficacy of pembrolizumab plus lenvatinib in RCC with rhabdoid features.

Indexed as

LenvatinibPembrolizumabRenal cell carcinomaRhabdoid feature

Identifiers

PMID40747481
PMCPMC12311438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.